Cargando…

Impact of Inflammation on Voriconazole Exposure in Critically ill Patients Affected by Probable COVID-19-Associated Pulmonary Aspergillosis

(1) Background: To explore the impact of the degree of inflammation on voriconazole exposure in critically ill patients affected by COVID-associated pulmonary aspergillosis (CAPA); (2) Methods: Critically ill patients receiving TDM-guided voriconazole for the management of proven or probable CAPA be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gatti, Milo, Fornaro, Giacomo, Pasquini, Zeno, Zanoni, Andrea, Bartoletti, Michele, Viale, Pierluigi, Pea, Federico
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134964/ https://www.ncbi.nlm.nih.gov/pubmed/37107125 http://dx.doi.org/10.3390/antibiotics12040764

Ejemplares similares

Relationship between Pharmacokinetic/Pharmacodynamic Target Attainment and Microbiological Outcome in Critically Ill COVID-19 Patients with Documented Gram-Negative Superinfections Treated with TDM-Guided Continuous-Infusion Meropenem
por: Sanz Codina, Maria, et al.
Publicado: (2022)

An Evidence-Based Multidisciplinary Approach Focused at Creating Algorithms for Targeted Therapy of BSIs, cUTIs, and cIAIs Caused by Enterobacterales in Critically Ill Adult Patients
por: Gatti, Milo, et al.
Publicado: (2021)

Targeted Therapy of Severe Infections Caused by Staphylococcus aureus in Critically Ill Adult Patients: A Multidisciplinary Proposal of Therapeutic Algorithms Based on Real-World Evidence
por: Gatti, Milo, et al.
Publicado: (2023)

An Evidence-Based Multidisciplinary Approach Focused on Creating Algorithms for Targeted Therapy of Infection-Related Ventilator-Associated Complications (IVACs) Caused by Pseudomonas aeruginosa and Acinetobacter baumannii in Critically Ill Adult Patients
por: Gatti, Milo, et al.
Publicado: (2021)

Real-Time TDM-Based Expert Clinical Pharmacological Advice Program for Attaining Aggressive Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Meropenem in the Treatment of Critically Ill Patients with Documented Gram-Negative Infections Undergoing Continuous Veno-Venous Hemodiafiltration
por: Gatti, Milo, et al.
Publicado: (2023)

Expert clinical pharmacological advice may make an antimicrobial TDM program for emerging candidates more clinically useful in tailoring therapy of critically ill patients
por: Gatti, Milo, et al.
Publicado: (2022)

Successful Treatment of Bacteremia and Ventilator-Associated Pneumonia Caused by KPC/OXA-48-like Klebsiella pneumoniae Co-Producer with a Continuous Infusion of High-Dose Meropenem Plus Fosfomycin Guided by Real-Time Therapeutic Drug Monitoring
por: Cojutti, Pier Giorgio, et al.
Publicado: (2022)

Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs
por: Gatti, Milo, et al.
Publicado: (2021)

Relationship Between Real-time TDM-guided Pharmacodynamic Target Attainment of Continuous Infusion Beta-lactam Monotherapy and Microbiologic Outcome in the Treatment of Critically Ill Children With Severe Documented Gram-negative Infections
por: Gatti, Milo, et al.
Publicado: (2023)

The Gut Microbiota of Critically Ill Patients With COVID-19
por: Gaibani, Paolo, et al.
Publicado: (2021)

Impact of Maximizing Css/MIC Ratio on Efficacy of Continuous Infusion Meropenem Against Documented Gram-Negative Infections in Critically Ill Patients and Population Pharmacokinetic/Pharmacodynamic Analysis to Support Treatment Optimization
por: Cojutti, Pier Giorgio, et al.
Publicado: (2021)

Voriconazole-refractory invasive aspergillosis
por: Park, Se Yoon, et al.
Publicado: (2017)

Assessment of a PK/PD Target of Continuous Infusion Beta-Lactams Useful for Preventing Microbiological Failure and/or Resistance Development in Critically Ill Patients Affected by Documented Gram-Negative Infections
por: Gatti, Milo, et al.
Publicado: (2021)

Pharmacokinetic/Pharmacodynamic Analysis of Continuous-Infusion Fosfomycin in Combination with Extended-Infusion Cefiderocol or Continuous-Infusion Ceftazidime-Avibactam in a Case Series of Difficult-to-Treat Resistant Pseudomonas aeruginosa Bloodstream Infections and/or Hospital-Acquired Pneumonia
por: Gatti, Milo, et al.
Publicado: (2022)

Role of a Real-Time TDM-Based Expert Clinical Pharmacological Advice Program in Optimizing the Early Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Beta-Lactams among Orthotopic Liver Transplant Recipients with Documented or Suspected Gram-Negative Infections
por: Gatti, Milo, et al.
Publicado: (2023)

Fast and Simple Liquid Chromatography-Isotope Dilution Tandem Mass Spectrometry Method for Therapeutic Drug Monitoring of Dalbavancin in Long-Term Treatment of Subacute and/or Chronic Infections
por: Barone, Rossella, et al.
Publicado: (2023)

Fast and Sensitive Analysis of Cefiderocol in Human Plasma Microsamples by Liquid Chromatography-Isotope Dilution Tandem Mass Spectrometry for Therapeutic Drug Monitoring
por: Barone, Rossella, et al.
Publicado: (2023)

Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin–Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative Infections
por: Berrino, Pasquale Maria, et al.
Publicado: (2023)

Fast and Sensitive Method for Simultaneous Quantification of Meropenem and Vaborbactam in Human Plasma Microsamples by Liquid Chromatography–Tandem Mass Spectrometry for Therapeutic Drug Monitoring
por: Barone, Rossella, et al.
Publicado: (2023)

Orbital Aspergillosis: Voriconazole – The New Standard Treatment?
por: Ohlstein, Derek H., et al.
Publicado: (2012)

A Proof of Concept of the Usefulness of a TDM-Guided Strategy for Optimizing Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Ampicillin-Based Regimens in a Case Series of Patients with Enterococcal Bloodstream Infections and/or Endocarditis
por: Gatti, Milo, et al.
Publicado: (2022)

Real-Time Optimization of Pharmacodynamic Target Attainment at Infection Site during Treatment of Post-Neurosurgical Ventriculitis Caused by Carbapenem-Resistant Gram Negatives with Ceftazidime–Avibactam-Based Regimens: A Report of Two Cases
por: Gatti, Milo, et al.
Publicado: (2022)

Therapeutic Drug Monitoring of Sputum Voriconazole in Pulmonary Aspergillosis
por: Sarfati, Sacha, et al.
Publicado: (2022)

Antiviral activity of interferon-based combination therapy in critically ill patients with COVID-19: Preliminary observations
por: Gaibani, Paolo, et al.
Publicado: (2021)

Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic: a multicentre cohort study
por: Pascale, Renato, et al.
Publicado: (2021)

Antimicrobial Dose Reduction in Continuous Renal Replacement Therapy: Myth or Real Need? A Practical Approach for Guiding Dose Optimization of Novel Antibiotics
por: Gatti, Milo, et al.
Publicado: (2021)

The Cytokine Release Syndrome and/or the Proinflammatory Cytokines as Underlying Mechanisms of Downregulation of Drug Metabolism and Drug Transport: A Systematic Review of the Clinical Pharmacokinetics of Victim Drugs of this Drug–Disease Interaction Under Different Clinical Conditions
por: Gatti, Milo, et al.
Publicado: (2022)

Prevalence of COVID-19-Associated Pulmonary Aspergillosis: Critical Review and Conclusions
por: Egger, Matthias, et al.
Publicado: (2022)

Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock – does the dose matter?
por: Pea, Federico, et al.
Publicado: (2009)

Management of invasive aspergillosis in patients with COPD: Rational use of voriconazole
por: Ader, Florence, et al.
Publicado: (2009)

Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial
por: Cadranel, J., et al.
Publicado: (2012)

Measuring Creatinine Clearance Is the Most Accurate Way for Calculating the Proper Continuous Infusion Meropenem Dose for Empirical Treatment of Severe Gram-Negative Infections among Critically Ill Patients
por: Troisi, Carla, et al.
Publicado: (2023)

Pharmacology and metabolism of voriconazole and posaconazole in the treatment of invasive aspergillosis-review of the literature
por: Sandherr, M, et al.
Publicado: (2011)

Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin - review of the literature
por: Karthaus, M
Publicado: (2011)

The pharmacokinetic challenge of voriconazole therapy for cerebral aspergillosis in patients treated with ibrutinib
por: Nyga, Rémy, et al.
Publicado: (2019)

Cost-effectiveness analysis of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis in Spain
por: Grau, Santiago, et al.
Publicado: (2016)

A Proof of Concept of the Role of TDM-Based Clinical Pharmacological Advices in Optimizing Antimicrobial Therapy on Real-Time in Different Paediatric Settings
por: Gatti, Milo, et al.
Publicado: (2021)

Breakthrough invasive fungal infections in liver transplant recipients exposed to prophylaxis with echinocandins vs other antifungal agents: A systematic review and meta‐analysis
por: Gatti, Milo, et al.
Publicado: (2021)

Critically ill patients with COVID-19 show lung fungal dysbiosis with reduced microbial diversity in patients colonized with Candida spp.
por: Viciani, Elisa, et al.
Publicado: (2022)

Clinically Significant Drug Interactions Between Psychotropic Agents and Repurposed COVID-19 Therapies
por: Gatti, Milo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_asecc7duaub8ntiqqqccrq3je2